Toward more effective gene delivery by Chen, Hannah H et al.
Genome B Bi io ol lo og gy y   2008, 9 9: :301
Meeting report
T To ow wa ar rd d   m mo or re e   e ef ff fe ec ct ti iv ve e   g ge en ne e   d de el li iv ve er ry y
Hannah H Chen, Ryan Cawood and Leonard W Seymour
Address: Oxford Institute for Cancer Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7BN, UK.
Correspondence: Leonard W Seymour. Email: Len.Seymour@clinpharm.ox.ac.uk
Published: 18 January 2008
Genome B Bi io ol lo og gy y 2008, 9 9: :301 (doi:10.1186/gb-2008-9-1-301)
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2008/9/1/301
© 2008 BioMed Central Ltd 
A report on the symposium ‘In vivo barriers to gene
delivery’, Cold Spring Harbor, USA, 26-29 November 2007.
Many different obstacles impede the in vivo efficiency of
both viral and non-viral agents for gene delivery. A recent
symposium at the Cold Spring Harbor Laboratory, New
York, addressed the latest approaches to overcoming these
barriers. Topics encompassed diverse technologies for
preventing vector neutralization, enhancing the persistence
of transgene expression and the use of modified measles coat
proteins to allow receptor specific HIV-1 pseudotyping.
M Mi is sl lo oc ca al li iz za at ti io on n, ,   s se eq qu ue es st tr ra at ti io on n   a an nd d   t ta ar rg ge et ti in ng g
Successful gene delivery depends on selective and efficient
localization to target tissues. However, many current
approaches are frustrated both by mislocalization and by
sequestration in non-target sites. Approaches presented at
the meeting that aim to circumvent these barriers include
alterations to viral coat proteins, the coating of viruses with
polymers and the tissue-specific repression of viral
replication by endogenous microRNAs.
Genetic modification of viruses can endow tumor-selective
replication, controlled by specific components of the tumor
phenotype. However, site-specific targeting of these ‘onco-
lytic’ viruses to tumor cells often depends on an increased
density of the virus receptor on the cancer cell surface
relative to other cells. This means that such viruses are
selective for tumor cells rather than absolutely specific, and
an important aim of work in this area is to increase
selectivity. Stephen Russell (Mayo Foundation, Rochester,
USA) described work using a measles virus that efficiently
enters and fuses cells via the cell-surface receptor CD46. He
showed that viral entry increases linearly with CD46 density
but that cell fusion is dependent on a threshold level of the
receptor. Moreover, by fusing measles virus H coat proteins
to ligands for different cell surface receptors, including the
epidermal growth factor receptor (EGFR) and the CD38 cell-
surface protein, it was demonstrated that this phenomenon
is not receptor specific. Russell showed that by fusing
measles H protein with different single-chain antibodies to
Her2, another member of the EGFR family, to increase the
affinity of the virus for the receptor, fusion could occur at
lower receptor densities. This finding may prove important
for many viral retargeting strategies, in which the affinity of
a retargeting ligand could be correlated with receptor
density on the cancer cell surface in order to mediate
selective intercellular fusion.
The use of pseudotyped viruses, expressing exogenous viral
envelope proteins, permits modified tropism while retaining
desirable viral properties. Sabrina Funke (Paul-Ehrlich
Institute, Langen, Germany) showed that truncation of the
cytoplasmic tails of measles virus H and F proteins was
necessary to allow pseudotyping of a lentiviral vector (HIV-1).
By inserting single chain variable fragments of a CD20
ligand in the ectodomain of modified measles virus H protein,
both successful targeting and transduction of CD20 positive
cells was confirmed by the modified HIV-1 vector. This
CD20-retargeted HIV vector successfully transduced >70%
of primary B cells in vitro, compared with an established
CD20-retargeted HIV vector (based on the Vesicular
Stomatitis virus glycoprotein) which gave only 18%
transduction. These results show a promising step towards
stable B cell-specific gene delivery.
Mislocalization and sequestration by non-target tissues are
major hurdles in the systemic use of tumor-destroying
viruses. The intravenous administration of adenovirus is
currently hindered by significant loss (99% of injected dose)
of viral particles to multiple non-target sites, including
hepatocytes and Kupffer cells (hepatic macrophages). The
consequence of such sequestration is a significant reduction
in circulating infectious particles available for infection of
tumor cells. One of us (LWS) described how cloakingadenovirus with reactive multivalent polymers based on
poly[N-(2-hydroxypropyl)methacrylamide] decreased both
infection of hepatocytes and virus phagocytosis by macro-
phages, increasing the percentage of injected dose in the
circulation from 4% to 48% 30 minutes after an intravenous
injection in mice. Moreover, the depletion of macrophages
using clodronate liposomes together with polymer cloaking
extended the circulating half-life of viral particles from 3
minutes to 120 minutes. This significant improvement in the
amount of circulating adenovirus may increase tumor
infection by allowing an extended period for passive and
tumor-specific targeting.
V Ve ec ct to or r   n ne eu ut tr ra al li iz za at ti io on n
Viral gene-delivery vectors, in particular those administered
intravenously, face an array of challenges from the innate
and adaptive immune systems, which rapidly diminish the
availability of vectors for delivery to target sites. Robert
Carlisle (Oxford University, UK) described how following
addition of human adenovirus type 5 (Ad5) to fresh whole
human blood, virus particles associated almost exclusively
with the cell fraction. Further investigation revealed that
binding to erythrocytes accounted for most (more than 90%)
of this interaction and that heat inactivation of plasma
abrogated this binding. Carlisle showed that complement
protein C3 and the complement receptor 1 (CR1) on human
erythrocytes are instrumental in this binding, revealing
these as potentially important targets for the inhibition of
Ad5-erythrocyte association.
These findings were complemented by a study presented by
Zhili Xu (Food and Drug Administration, Bethesda, USA)
elucidating the molecular mechanisms underlying the
nonspecific uptake of adenovirus by murine liver Kupffer
cells - a major pathway for clearing circulating virus particles.
Administration of scavenger receptor antagonists, such as
poly(inosinic acid), was shown to decrease Kupffer cell
capture of Ad5 in vivo, although clearance was not affected
by non-scavenger receptor-binding polyanions. This study
also showed the binding of Ad5 to complement proteins C3
and C4 and the likely involvement of this interaction for the
recognition of Ad5 by Kupffer cells. Notably, the authors
demonstrated that serum from naïve mice contained IgM
capable of binding virus, and this raised the possibility that
‘natural’ antibodies might play a role in complement fixation
and Kupffer cell clearance. This was reinforced by the
observation that antibody-deficient Rag1-knockout mice
showed decreased Kupffer cell capture.
The inflammatory effects triggered by the detection of viral
antigens by the immune system tend to suppress viral infec-
tion, thus posing another substantial obstacle to the success
of viral vectors. Michael Roberts (Wellstat Biologics
Corporation, Gaithersburg, USA) has investigated the
effects of different dosing regimes and infusion rates on
humans in an attempt to desensitize the immune system to
the introduced virus and thus reduce the release of pro-
inflammatory cytokines. He found that slower rates of
infusion (typically infused over four hours) enhanced
tolerance to intravenously administered oncolytic Newcastle
disease virus. These observations may inspire further
endeavors aimed at managing the immunological challenges
confronting systemic delivery of therapeutic viruses.
John Bell (Ottawa Health Research Institute, Montreal,
Canada) described a mutant strain of oncolytic vesicular
stomatitis virus (VSV) that has a preference for productive
infection of tumor cells. This strain (VSV∆51) has a mutation
in a protein necessary for the intracellular transport of the
host-cell mRNA for the antiviral protein interferon-β. Bell
also described the screening of a variety of histone deacetylase
inhibitors (HDACIs) as novel pharmacological agents to
downregulate interferon production, and the finding that
some synergized dramatically with the oncolytic VSV strain,
increasing its growth in monolayers and tumor explants as
well as in vivo in a highly tumor-specific manner. Down-
regulation of interferon production by HDACIs is a
potentially valuable approach to augment the oncolytic
potency of viruses, in particular those with an attenuated
ability to suppress host interferon responses.
P Pe er rs si is st te en nc ce e   o of f   r re ec co om mb bi in na an nt t   v vi ir ra al l   v ve ec ct to or rs s
The durability of transgene expression from viral vectors is
often limited by activation of immune components.
Recombinant adeno-associated virus (AAV) vectors have
received much attention recently as they are maintained
episomally to achieve sustained therapeutic gene expression.
An emerging problem preventing the persistence of AAV-
introduced genes is a cytotoxic CD8 T-cell response that is
elicited against AAV capsid antigens in humans. Federico
Mingozzi (Children’s Hospital of Philadelphia, USA)
reported the observation of T-cell activation following intra-
muscular injection of an AAV-1 vector carrying a lipoprotein
lipase transgene, which was correlated with the loss of
therapeutic efficacy. Such immune stimulation was not
induced in response to transgene-derived antigens, but was
generated specifically against the AAV-1 capsid. Further-
more, activated CD8 T cells were shown to cross-react with
other AAV  serotypes. Similar effects were reported by
Katherine High (Children’s Hospital of Philadelphia, Penn-
sylvania, USA) in a clinical trial using AAV vectors for the
genetic treatment of hemophilia, where patients developed
treatment-limiting anti-AAV capsid responses that had not
been observed in mouse studies. This capsid-directed
immunity is clearly a setback for the clinical development of
this vector.
In regard to responses to AAV in mice, however, Hildegund
Ertl (Wistar Institute, Philadelphia, USA) described a study
in mice in which a recombinant AAV vector expressing the
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transgene product-specific CD8 T cells that were impaired in
their ability to proliferate and in their cytotoxic function.
This phenomenon, termed T-cell exhaustion, was shown to
be a consequence of continual exposure to the antigen and
was reversed if the CD8 T cells were removed from the
presence of the antigen.
These different observations may reflect differences in the
previous exposure of human patients and laboratory animals
to AAV. Prior exposure to AAV in the environment could
have resulted in a pool of memory CD8 T cells in the human
patients, whereas naive animals would be expected to
respond differently to the virus. Together, these findings
suggest the importance of conducting studies in animals that
have been previously exposed to such vectors.
Preventing premature termination of transgene expression
is also important in cancer, particularly where treatment is
intended to act over an extended period. Retroviruses
cannot penetrate an intact nuclear membrane and so
exclusively infect actively dividing cells; this property
enables them to be used to selectively target proliferating
tumor cells. Noriyuki Kasahara (University of California, Los
Angeles, USA) described replication-competent retroviruses
(RCR; based on murine leukemia virus) armed with genes
promoting cell suicide (apoptosis). These exhibited high
anti-tumor efficacy in vivo, in mice, which was partly
attributable to persistent expression of the transgene from
residual infected tumor cells, increasing the effectiveness of
repeated administration of a prodrug. This strategy may
offer an efficient means of controlling tumor regrowth and
metastasis. Kasahara described how the technology is
currently being augmented by tumor-specific transcriptional
targeting and the development of RCR vectors with the
capacity to suppress cellular innate immune responses. He
also described an innovative approach using adenovirus-
retrovirus hybrid vectors consisting of an adenovirus
encoding all the components required for the production of a
retrovirus upon target-cell infection. This allows desirable
features such as high adenoviral transduction efficiency and
stable retroviral integration into the genome to be combined.
Advancement in gene-delivery technologies has been largely
hampered by difficulties in overcoming the multitude of
physical, metabolic and immunological barriers that prevent
potentially powerful exogenous genetic material from exerting
its full therapeutic benefit. Deeper insights into and under-
standing of these in vivo obstacles will aid in the development
of technologies for vector design and delivery, with the
ultimate aim of efficient, safe and efficacious gene therapy.
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